Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ TLE4 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA540533
Description
Peptide sequence: GAEKHRNSAD YSSESKKQKT EEKEIAARYD SDGEKSDDNL VVDVSNEDPS Sequence homology: Cow: 93%; Dog: 100%; Guinea Pig: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Rabbit: 100%; Rat: 100%.
Transcriptional corepressor that binds to a number of transcription factors. Inhibits the transcriptional activation mediated by PAX5, and by CTNNB1 and TCF family members in Wnt signaling. The effects of full-length TLE family members may be modulated by association with dominant-negative AES.
Specifications
TLE4 | |
Polyclonal | |
Unconjugated | |
TLE4 | |
5730411M05Rik; AA792082; B lymphocyte gene 1; BCE1; BCE-1; E(spI); enhancer of split groucho 4; ESG; ESG4; Esp2; ESTM13; ESTM14; GRG4; Grg-4; groucho-related protein 4; KIAA1261; Protein ESP2; TLE family member 4, transcriptional corepressor; Tle4; transducin like enhancer of split 4; transducin-like enhancer of split 4; transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila); transducin-like enhancer of split 4, E(spl) homolog; transducin-like enhancer of split 4, homolog of Drosophila E(sp1); transducin-like enhancer of split 4, homolog of Drosophila E(spl); transducin-like enhancer protein 4; X83332; X83333 | |
Rabbit | |
Affinity Chromatography | |
RUO | |
7091 | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid |
Immunohistochemistry, Western Blot | |
0.5 mg/mL | |
PBS with 2% sucrose and 0.09% sodium azide | |
Q04727 | |
TLE4 | |
Synthetic peptide directed towards the N-terminal of human TLE4 (aa 215-264). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction